The YouTuber suggests HRTS as a bonus fund focusing on companies fighting obesity and cardiometabolic diseases, including small-cap firms. He points to the massive market opportunity in GLP-1 drugs, the high obesity rates, and the fund's strong year-to-date performance and analyst ratings for significant upside.
“This hrts fund well it happens to be very new but it's up 133% year-to date and up 29% since Inception... an analyst gives the fund a strong buy with 46% upside for the next 12 months.” — ▶ 7:00